Novoste Narrows Focus For Primary Indication In Light Of Beta-Cath Trial
This article was originally published in The Gray Sheet
Executive Summary
Novoste Corp. is considering further evaluation of its Beta-Cath radiation system using a longer source train and a smaller diameter catheter in conjunction with initial angioplasty treatment.